NEW: Amyloid diseases that affect the brain, such as Alzheimer’s and Parkinson’s diseases, receive the lion’s share of attention — but there is growing medical appreciation that amyloid diseases affect tissues beyond the brain. ✍️ @amberldance knowablemagazine.org/article/health…

I'm quoted in this great article about systemic amyloidosis by @amberldance which explains how our research BU Amyloidosis Center fits into the bigger medical challenge. Also featuring Isabelle Lousada of Amyloidosis Research Consortium knowablemagazine.org/article/health…

ARC is pushing research forward today, on #NationalAmyloidosisDay, and everyday. Our programs like the #AmyloidosisForum are a model for collaboration garnering support from the NIH and Members of Congress like Jake Auchincloss: arci.org/nih-grant-2023/

Congratulations to Dr Elena Klimtchuk of BU Amyloidosis Center in elucidating mechanism of amyloid fibrillogenesis. Role of complementarity-determining regions 1 and 3 in pathologic amyloid formation by human immunoglobulin κ1 ligh… pubmed.ncbi.nlm.nih.gov/37216473/

A review of our work to develop stabilizer drugs for AL amyloidosis is out today in Current Opinion in Chemical Biology: authors.elsevier.com/c/1hCX74sz6MIp… Highlights the work of Scripps Research Graduate Program alum Nick Yan, who developed high-efficacy molecules against a non-traditional drug target

The first generation of drug approvals in #ATTR #amyloidosis has reshaped the research landscape. This month's #AmyloidosisForum will consider how to effectively design trials against a backdrop of treatments that slow progression of the disease. amyloidosisforum.org/attr-drug-deve…

Kristian G. Andersen Statement to a congress is a breath of #sanity in an increasingly delusional, weaponized anti-science atmosphere created by conspiracy theorists and their self-serving amplifiers in media and politics. Worth reading in full, top to bottom: oversight.house.gov/wp-content/upl…

Online now (The International Society Of Amyloidosis)! S/o to Sabrina Ghosh for her hard work during the pandemic (this was her UNDERGRAD❗️thesis)! HUGE thanks to the 🐐 mentor George J. Murphy for letting me play junior PI (my first (and hopefully not last) senior author paper🥸) tandfonline.com/doi/full/10.10…

Big day for patients with ATTR amyloidosis, as the topline results of ATTRIBUTE-CM are positive! Acoramidis showed significant benefit for the hierarchical composite of all-cause mortality, CV hospitalization, NTproBNP, and 6MW distance. investor.bridgebio.com/news-releases/…

The Scripps Research community mourns the passing of Michael Oldstone, MD, esteemed virologist and professor emeritus, who helped establish the viral pathogenesis field and shaped our understanding of host immune responses scripps.edu/news-and-event…

With apologies to Yiying Lu.

15 cases of AGelsolin amyloidosis: largest series in the US. 20% renal involvement, 7% cardiac involvement besides cranial, peripheral and autonomic neuropathy. @lis589 Vaishali Sanchorawala pubmed.ncbi.nlm.nih.gov/37140928/

Mechanisms on pathophysiology of amyloid fibrillogenesis form BU Amyloidosis Center Gareth Morgan Kinetic evidence for multiple aggregation pathways in antibody light chain variable domains pubmed.ncbi.nlm.nih.gov/38100259/

DepleTTR-CM trial is now on clinicaltrials.gov Phase III trial of ALXN2220 (NI006) vs placebo Fibril remover ( phase I results nejm.org/doi/full/10.10… ) 1000 patients, ATTR-CM, loop diuretics, NTproBNP > 2000. PEP: ACM+CV events classic.clinicaltrials.gov/ct2/show/NCT06… #CardioTwitter

Fantastic to see our competitive, market-driven healthcare system in action as BridgeBio launches a newly-approved TTR stabilizer molecule at a list price that's [checks notes] 10% higher than the indistinguishable competitor?